Navigation Links
Tackling Atrial Fibrillation and Associated Cardiovascular Risk
Date:11/4/2008

- RecordAF Registry Baseline Data and New Data from the Landmark ATHENA

Study
PARIS, Nov. 4 /PRNewswire/ --

Live Webcast Media Briefing - non-US media only

Wednesday 12 November 2008 - 14.00-15.00am CET

Background:

-- AF is a growing health concern directly responsible for increased

morbidity and mortality

-- There is a need for a global prospective database like RecordAF, which

takes a closer look at disease characteristics and how management of AF

affects cardiovascular (CV) outcomes

-- AF is associated with a high hospitalization burden - 70 percent of AF

management costs are driven by hospitalization costs (Ringborg et al.

Europace 2008; 10:403-11)

-- A further sub-analysis of the ATHENA trial was conducted:

-- to better understand the impact of dronedarone on hospitalization

of AF patients particularly on the number and duration of CV and

non CV hospitalization nights

-- An additional sub-analysis was also conducted to further explore

dronedarone's rhythm and rate controlling properties

-- The ATHENA study is the first AF trial designed to evaluate the effect

of an anti arrhythmic drug (AAD) on morbidity and mortality. It showed

that dronedarone (brand name Multaq(R)), a new AAD undergoing the

registration process, can significantly improve CV outcomes including

reducing the risk of hospitalization and death.

Register on-line in advance of the online event:

1. Go to https://sanofiaventismediabriefing.webex.com/sanofiaventismediabriefing/ons t age/g.php?d=702842657&t=a&EA=nburns%40webex.com&ET=6b1f2c181b8fa5176928ed1c 72 009c4d&ETR=8789fb6f20765cb360e4d0c88cea0f23 (due to the length of this URL, please copy a
'/>"/>

SOURCE Sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Texas Cardiac Arrhythmia Institute at St. Davids Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation
2. Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
3. Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
4. Catheter Ablation System for Atrial Fibrillation Shows Reduced Procedure Time, Remarkable Safety Profile and Excellent Outcomes in Two Clinical Studies
5. American Heart Journals Publishes Results From ERATO Trial Showing Dronedarone (Multaq(R)) Improves Ventricular Rate Control in Patients With Permanent Atrial Fibrillation
6. Multaq(R) (dronedarone) Granted FDA Priority Review for Patients with Atrial Fibrillation
7. Studies of an Innovative Catheter Ablation System for Atrial Fibrillation Reveal Excellent Outcomes, Safety Profile and Fast Procedure Times
8. Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
9. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
10. ATS Medical Announces Initial Clinical Results of Stand-Alone Atrial Fibrillation Procedures Using ATS CryoMaze Product Line
11. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... -- HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the second quarter ended June 30, 2014, a ... the same period of 2013. During the ... were sold globally compared to 523 units in the ...
(Date:7/31/2014)... 2014 Second Quarter Total Revenue $2.0 billion; an increase of ... 4% for same store sales and 8% pro forma, excluding ... , 2014 Second Quarter GAAP EPS $0.37; Cash EPS $1.91, ... Operating Cash Flow $376 million; Adjusted Operating Cash Flow $500 ... Launched 17 new products in the U.S. year-to-date , ...
(Date:7/31/2014)... , 31 juli 2014 De Pfizer ... een rekruteringscampagne voor gezonde vrijwilligers van Japanse komaf voor ... gevestigde PCRU is één van twee onderzoekseenheden ... als ideaal levens te verbeteren door de ontdekking en ... de PCRU op zoek naar mannen en vrouwen van ...
Breaking Medicine Technology:HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 2HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 3HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 4HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 5HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 6HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 7HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 8HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 9HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 10HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 11HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 12Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 2Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 3Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 4Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 5Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 6Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 7Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 8Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 9Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 10Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 11Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 12Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 13Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 14Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 15Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 16Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 17Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 18Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 19Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 20Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 21Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 22Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 23Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 24Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 25
... PARSIPPANY, N.J., Sept. 15, 2011 Fidia Farmaceutici S.p.A. ... ® (sodium hyaluronate), an injectable treatment for knee ... and physical therapy are not enough, will be transferred ... 24, 2011.  Fidia Farmaceutici S.p.A. is the owner and ...
... September 15, 2011 Oramed Pharmaceuticals Inc. ... oral delivery systems, announced today that Ehud Arbit, M.D., ... present at the 8th Annual Israel Strategic Partner and ... Bristol-Myers Squibb Pharmaceutical Research Institute in Princeton, NJ on ...
Cached Medicine Technology:HYALGAN® (sodium hyaluronate) Commercial Rights Transfer Back to Fidia Farmaceutici S.p.A. 2Oramed Pharmaceuticals Chosen to Present at the 8th Annual Israel Strategic Partner and Venture Conference on September 22, 2011 2
(Date:7/31/2014)... Thousands of independent community pharmacists, ... have come together today to kick off ThoughtSpot ... , "ThoughtSpot 2014 is Good Neighbor Pharmacy’s annual ... to help their businesses thrive," stated AJ Caffentzis, ... long-standing commitment to independent community pharmacies, and at ...
(Date:7/31/2014)... 31, 2014 Web Programming Services, a ... certified internet marketing firm, has recently launched a new ... this service affordable for everyone, the company has announced ... , Web Programming Services has tailored the service ... brochure designing and likely expectations of the clients from ...
(Date:7/31/2014)... Agebc.com, a popular online shop of wedding dresses and women’s ... mother of the bride dresses . Aside from that, ... to 68% off. , “We are proud to enrich ... of the bride dresses. We launch the special offer to ... shop has received thousands of rave reviews from new and ...
(Date:7/31/2014)... new study by researchers at Sanford-Burnham Medical Research Institute ... convert existing cells in the pancreas into those cells ... published online July 31 in Cell Death and ... estimated 3 million people in the U.S., and over ... "We have found a promising technique for type 1 ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Quincy Bioscience, ... of brain health supplement Prevagen®, releases the second edition ... Marvelous Tips for Making Memories: Birth of a Grandchild. ... that offers exceptional memory-making tips and ideas for grandparents ... birth of a grandchild. Each concept published in the ...
Breaking Medicine News(10 mins):Health News:Good Neighbor Pharmacy’s ThoughtSpot Begins Today with Record Attendance 2Health News:Good Neighbor Pharmacy’s ThoughtSpot Begins Today with Record Attendance 3Health News:Web Programming Services Introduces Affordable Brochure Designing Service 2Health News:Mother of the Bride Dresses Now Available With Great Discounts at Agebc.com 2Health News:A new way to generate insulin-producing cells in Type 1 diabetes 2Health News:Quincy Bioscience Launches the Second E-Book of the Making Memories Series 2
... Surprising finding shows it reduces risk of death, recurrence , ... soy foods can help lower the risk of death and ... shows. , What,s more, the association between soy and a ... estrogen receptor-positive cancers and women taking tamoxifen, according to the ...
... ... that a new market research report is available ... for Interventional Cardiology 2009 (15 Countries) ... European market for interventional cardiology was valued at ...
... , ... new market research report is available in its catalogue: ... Players, and Important Trends) , http://www.reportlinker.com/p0167109/EMR-2010-Market-Analysis-ARRA-Incentives-Key-Players-and-Important-Trends.html ... Kalorama Information surveyed the market for electronic medical records. ...
... your cool with misbehaving children is a challenge. We all ... out at someone without thinking. A new study by ... parents with poorer working memory skills are less likely to ... "Angry, oppositional behavior in children is aversive and challenging to ...
... , Woodbury, N.Y., Dec. 8 On December 9 ... and Miami schools to perform the live nutrition rock concert, ... Dietitian and musician is appearing free to schools courtesy of ... programs. This interactive show promotes healthy eating by ...
... Dec. 8 Tipping Point Community, a charitable organization dedicated ... million donation from the Sergey Brin and Anne Wojcicki Foundation. ... Annual Awards Breakfast and is one of Tipping Point,s largest ... one-quarter of families are too poor to meet their basic ...
Cached Medicine News:Health News:Soy Beneficial for Breast Cancer Survivors: Study 2Health News:Soy Beneficial for Breast Cancer Survivors: Study 3Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 2Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 3Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 4Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 5Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 6Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 7Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 8Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 9Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 10Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 11Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 12Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 13Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 14Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 15Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 16Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 17Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 18Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 19Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 20Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 21Health News:Reportlinker Adds EMR 2010 (Market Analysis, ARRA Incentives, Key Players, and Important Trends) 2Health News:Reportlinker Adds EMR 2010 (Market Analysis, ARRA Incentives, Key Players, and Important Trends) 3Health News:Reportlinker Adds EMR 2010 (Market Analysis, ARRA Incentives, Key Players, and Important Trends) 4Health News:Reportlinker Adds EMR 2010 (Market Analysis, ARRA Incentives, Key Players, and Important Trends) 5Health News:Reportlinker Adds EMR 2010 (Market Analysis, ARRA Incentives, Key Players, and Important Trends) 6Health News:Breakfast BREAKS(R) 'Jump with Jill' Rockin' Nutrition Show Kicks off Tour in Florida Schools 2Health News:Tipping Point Community Announces $1 Million Gift at Third Annual Awards Breakfast 2
The Astigmatome makes precise and accurate cuts for astigmatism correction simply and safely. Depth: 500 to 600....
The Astigmatome makes precise and accurate cuts for astigmatism correction simply and safely. Depth: 500 to 700....
Designed to remove cell debris or tissue remnants from the retina....
... Medtronic presents the Streamline family of ... have taken the gold standard in temporary ... that make them easy to use and ... Streamline Temporary Pacing Leads are designed to ...
Medicine Products: